{"id":1021273,"date":"2026-11-16T08:37:41","date_gmt":"2026-11-16T13:37:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/"},"modified":"2026-11-16T08:37:41","modified_gmt":"2026-11-16T13:37:41","slug":"corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/","title":{"rendered":"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed<\/li>\n<li>Corresponding significant reductions were also seen in waist circumference and body mass index (BMI)<\/li>\n<li>Treatment-emergent psychiatric adverse events (AEs) were infrequent, mostly mild, and in line with published GLP-1 data<\/li>\n<li>No serious or severe psychiatric AEs were reported, including no cases of severe or serious suicidality or depression<\/li>\n<li>Vomiting, nausea, and constipation occurred at lower rates and were milder than those reported in published studies of oral GLP-1s\n<\/li>\n<\/ul>\n<p>NORWOOD, Mass., Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), a clinical-stage company focused on developing new therapies in oncology and obesity, announced today that additional data from the CANYON-1 Phase 1b obesity study were presented in a\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rdKfcgqUz4eewvgapysle1qe1p6dD3lF0n1lSifCpUoTLUcRG8KhBk1YdIj6r6PnWwKoT1KqoWA92awjAkrMFo3W-JM4Qb8rBgIpvq9pO8neRubaSUAJc5zR_zXEuBxXdwooobAZ98Z0_lMnA0vS0ZYtkHD_bKoiJCc5fZu9RZtHt-pkSts1FhFy0oNcYmT-m6VFoVmMlXCCvqKKCILgbUK3l3Dn4lXxdfKFGElqfyBlb4fJ57b_rqZY0__GM8Q_iB4dI3a3LRg4iWCU37-nCvJCzyczaIPo1bO_8U2b375ZWY7P7j9yOli-wgW06ICAz2uM36TXQ7dAgxZdoXTOfG2h0LyVGJkB9SHxgiXU1rAYTMln01UdjqYgPjnWr1Z-oMpU91umPQ5JNPGJcF02uSE8WcFc3eFbR_G2mBohsb3WfhWnLnoHUcyz5G7aoriFTo5nR1ITlZX_nRRUzKb1mvdN2mZ7sRH0EypWIZoGF3qvrXk9nauaYCxppIAUSnpGlEEb17caZsMHgRTwcmhDqZ01oJb3ZsRAQwuD4YJMYBI=\" rel=\"nofollow\" target=\"_blank\">poster<\/a> at ObesityWeek<strong>\u00ae<\/strong> 2026.<\/p>\n<p>The data demonstrated statistically significant and clinically meaningful weight loss at all three doses of CRB-913, with the highest dose of 60 mg achieving a mean weight loss of 5% at 12 weeks. CRB-913 had a favorable safety and tolerability profile. \u00a0The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is line with published GLP-1 data. Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe treatment-emergent psychiatric AEs were reported. These data support CRB-913\u2019s potential to establish a new class of oral, non-incretin obesity medicines.<\/p>\n<p>\u201cWe\u2019re pleased to share the CANYON-1 trial data at ObesityWeek<strong>\u00ae<\/strong>. While the rise of incretin-based therapies has been remarkable, a significant number of people either do not adequately respond to or cannot tolerate these therapies, with more than 60% discontinuing treatment within the first year on these medicines,\u201d said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. \u201cIn the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We\u2019re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.\u201d<\/p>\n<p>\n        <strong>Study Design<\/strong>\n      <\/p>\n<p>The CANYON-1 Phase 1b clinical trial was a 16-week, double-blind, placebo-controlled, dose-ranging study that enrolled 254 obese, non-diabetic adult participants at 15 investigational sites in the United States (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4dAcUtagp7RiyJx2NtAFx7zqcbYaNlTQ6SVuxCwdzyoItu_ZMGdn569q8VowlXiBScXSl8nL8yVl4z8Mr3FINGe3uzomYWzjkuU2PdBxICBA-gIqoUO4EaWsfVtTKby9ezRFnfOMPSoStjoiDcz5aTfsWqC0sDeuMun32HjvhU4=\" rel=\"nofollow\" target=\"_blank\">NCT07310901<\/a>). The trial included three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once daily, as well as a placebo cohort (randomization ratio of 1:1:1:1). A dose titration regimen was used, with all participants receiving CRB-913 starting at 20 mg\/day and those assigned to the higher-dose cohorts titrating up every two weeks to either 40 mg\/day or 60 mg\/day, depending on their assigned cohort. Participants were dosed for 12 weeks and followed for an additional 4 weeks.<\/p>\n<p>\n        <strong>Efficacy<\/strong>\n      <\/p>\n<p>CRB-913 demonstrated rapid, statistically significant, and clinically meaningful weight loss at all dose levels, with no evidence of plateauing at any of the doses. Weight loss response rates were significantly higher across all three CRB-913 cohorts compared to the placebo cohort.<\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\u00a0<\/td>\n<td colspan=\"1\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>CRB-913<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:48%;width:48%;min-width:48%;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px\">\n            <strong>Cohort<\/strong>\n          <\/td>\n<td colspan=\"1\" style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Placebo<\/strong><br \/>\n            <br \/>(n = 66)<\/td>\n<td colspan=\"1\" style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>20 mg<\/strong><br \/>\n            <br \/>(n = 65)<\/td>\n<td colspan=\"1\" style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>40 mg<\/strong><br \/>\n            <br \/>(n = 61)<\/td>\n<td colspan=\"1\" style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>60 mg<\/strong><br \/>\n            <br \/>(n = 62)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px\">LS mean weight loss from baseline at week 12, %<sup>1<\/sup><\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">0.0%<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">2.8%<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">3.3%<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">5.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px\">LS mean weight loss at week 12, % (placebo-adjusted)<sup>1<\/sup><\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">NA<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">2.8%<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">3.3%<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">5.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px\">p-value vs. placebo<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">NA<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">&lt;0.0001<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">&lt;0.0001<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">&lt;0.0001<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px\">Change in waist circumference from baseline, cm<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">-0.84<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">-3.03<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">-3.04<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">-3.94<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px\">p-value<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">0.21<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">&lt;0.0001<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">&lt;0.0001<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">&lt;0.0001<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px\">BMI percent change from baseline<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">-0.06<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">-2.81<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">-3.34<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">-4.99<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px\">p-value<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt\">0.89<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">&lt;0.0001<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">&lt;0.0001<\/td>\n<td colspan=\"1\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt\">&lt;0.0001<\/td>\n<\/tr>\n<\/table>\n<p>\n        <sup>1<\/sup> Efficacy estimand. The LS means and p-values were derived using a mixed model for repeated measures (MMRM), with percent change from baseline as the dependent variable; sex, treatment group, visit, and the treatment group-by-visit interaction as categorical fixed effects; and baseline weight as a covariate. An unstructured covariance matrix was used.<\/p>\n<p>All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5.0% from baseline. Similarly, 6.7% of the participants in that cohort lost more than 7.5% of their weight from baseline. The highest recorded weight loss for this cohort was 13.4% from baseline. Participants treated with CRB-913 also experienced dose-dependent reductions in waist circumference and body mass index during the study.<\/p>\n<p>\n        <strong>Safety<\/strong>\n      <\/p>\n<p>CRB-913 was safe and well tolerated. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is in line with published GLP-1 data.<\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>CRB-913<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:40%;width:40%;min-width:40%;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">\n            <strong>Safety measure<\/strong>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Placebo<\/strong><br \/>\n            <br \/>(n = 66)<\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>20 mg<\/strong><br \/>\n            <br \/>(n = 65)<\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>40 mg<\/strong><br \/>\n            <br \/>(n = 61)<\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>60 mg<\/strong><br \/>\n            <br \/>(n = 62)<\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Total<\/strong><br \/>\n            <br \/>(N = 254)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Any TEAE, n (%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">28 (42.4)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">39 (60.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">45 (73.8)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">45 (72.6)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">157 (61.8)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">Severe TEAE<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">3 (4.6)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">2 (3.3)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">1 (1.6)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">6 (2.4)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">Severe psychiatric TEAE<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">Severe gastrointestinal TEAE<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)\u00a0<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">Serious TEAE<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">2 (3.1)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">1 (1.6)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">1 (1.6)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">4 (1.6)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Any TRAE, n (%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">14 (21.2)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">27 (41.5)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">34 (55.7)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">33 (53.2)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">108 (42.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">Severe TRAE<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">1 (1.6)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">1 (0.4)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">Serious TRAE<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0 (0.0)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Treatment discontinuation for any reason, n (%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">12 (18.2)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">10 (15.4)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">16 (26.2)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">16 (25.8)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">54 (21.3)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Treatment discontinuation due to an AE, n (%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">3 (4.5)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">2 (3.1)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">8 (13.1)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">8 (12.9)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">21 (8.3)<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>Psychiatric Adverse Events<\/strong>\n      <\/p>\n<p>Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe psychiatric AEs were reported.<\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>CRB-913<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:48%;width:48%;min-width:48%;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">\n            <strong>Adverse event, n (%)<\/strong>\n          <\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Placebo<\/strong><br \/>\n            <br \/>(n = 66)<\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>20 mg<\/strong><br \/>\n            <br \/>(n = 65)<\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>40 mg<\/strong><br \/>\n            <br \/>(n = 61)<\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>60 mg<\/strong><br \/>\n            <br \/>(n = 62)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Suicidality<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Depressive symptoms<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">1 (1.6%)<br \/>(moderate)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Anxiety<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">3 (4.5%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">2 (3.1%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">5 (8.2%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">3 (4.8%)<\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>Fifty percent of the psychiatric AEs occurred within the first 28 days, a pattern similar to that seen with GLP-1 analogs. No cases of suicidal ideation or serious or severe depression were observed. Psychiatric AEs did not appear to be dose-related; rates of depression and anxiety were in line with those reported in published GLP-1 studies. Only one of the 188 participants receiving CRB-913 reported transient, moderate depressive symptoms, a rate that is in line with published GLP-1 data. A total of 15 participants (8%) on CRB-913 reported mild irritability that was transient, resolved spontaneously, and did not affect their daily function. All 15 participants experienced weight loss, and 12 participants had concomitant unrelated AEs.<\/p>\n<p>\n        <strong>Gastrointestinal Adverse Events<\/strong>\n      <\/p>\n<p>Treatment-emergent gastrointestinal AEs were all mild or moderate, with no serious or severe events.<\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>CRB-913<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:48%;width:48%;min-width:48%;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">\n            <strong>Adverse event, n (%)<\/strong>\n          <\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Placebo<\/strong><br \/>\n            <br \/>(n = 66)<\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>20 mg<\/strong><br \/>\n            <br \/>(n = 65)<\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>40 mg<\/strong><br \/>\n            <br \/>(n = 61)<\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>60 mg<\/strong><br \/>\n            <br \/>(n = 62)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Vomiting<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">3 (4.6%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">5 (8.2%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">1 (1.6%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Nausea<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">3 (4.5%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">10 (15.4%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">16 (26.2%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">14 (22.6%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Constipation<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">2 (3.0%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">3 (4.6%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">1 (1.6%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">3 (4.8%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Diarrhea<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">2 (3.0%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">14 (21.5%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">16 (26.2%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">14 (22.6%)<\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>Vomiting, nausea, and constipation occurred at lower rates and were less severe than those reported in published studies of oral GLP-1s. Treatment discontinuations due to gastrointestinal AEs occurred in only three participants (two on CRB-913 and one on placebo).<\/p>\n<p>\n        <strong>Next Steps<\/strong>\n      <\/p>\n<p>Corbus plans to engage with the FDA to discuss the data and the development plans for CRB-913. The Company is also evaluating the potential for CRB-913 in combination with GLP-1 therapies.<\/p>\n<p>\n        <strong>About Corbus<\/strong>\n      <\/p>\n<p>Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus\u2019 pipeline includes SUTA-E (sutantatug envedotin), a next-generation antibody-drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered, highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aXgMHzlBo8NpOGtVte6kby_MXbAHvmqouPxjRFj92b5h48j0IWxGqqUAKihLxO8EL9DSgd_vmsLz7-gAyn8AEegBRbhdbdiDzHa2mb8Z29pY7innuZ4L71_7pITT8UV_WcxDiojr3bGyWe46nGieFgn1AY-2hwqj9tN3onLY5anDnEkEEZBVXYy73wX-HDyYfFxer0hNNey2bemmqoEOGvcaBbj66v8inaS6z63yshEZguKK2GMgTqvtte-15Wb8wPY5dMIqcxmmP_LDU7Y6yA==\" rel=\"nofollow\" target=\"_blank\">corbuspharma.com<\/a>. Connect with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=052iCOkSJLvyU8VShir7laxWLSs01APuLNTQOe0dlqewgO-r3YvnYJkmkAdl9qdwoivxmWZ9xhna7_8lc1XXEQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QhdcYUo1_N13HW4PAu4DzOWPqlqqwZSBBhTgbLqu7IGU7ud-cm3UsMVEfqZ6PJjVNiIVtBdgQYSosyCh4-km2JlVfWaDxn39lt5k_Di0OHnNlgNLc43AKnWUYd44dyi2\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cw3WYAxMzeGAhuy7LuD1ti8hm7_jCYR9lcvrx_c0UdytP0MSUI7rOVmC8F1swCxHOr4cB54kGIMjf2npKWF4FNGsoryvjAEMl9G61ebCuG0=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the potential benefits and development of CRB-913, future clinical studies and regulatory discussions, potential combination therapies, development timing and funding. They reflect current expectations and assumptions and are subject to risks and uncertainties that could cause actual outcomes to differ materially. These include the possibility that early clinical findings will not be reproduced in larger or longer studies; additional safety findings or changes following further analysis; delays in clinical or regulatory activities; and the availability and terms of financing or partnering arrangements. Further risks are described under the heading \u201cRisk Factors\u201d in Corbus most recent Annual Report on Form-10-K and subsequent Quarterly Reports on Form10-Q filed with the Securities and Exchange Commission. Forward-looking statements apply only as of the date of this release. Corbus does not undertake to update them except as required by law.<\/p>\n<p>\n        <strong>Investor Contacts<\/strong>\n      <\/p>\n<p>Sean Moran<br \/>Chief Financial Officer<br \/>Corbus Pharmaceuticals<br \/>smoran@corbuspharma.com<\/p>\n<p>Dan Ferry<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/>daniel@lifesciadvisors.com<\/p>\n<p>\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p>Liz Melone<br \/>Founder and Principal<br \/>Melone Communications, LLC<br \/>liz@melonecomm.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmQzNTAwMzUtOTFjYy00NjFlLWIxODctMmEzNmY3NzNlYzU4LTUwMDExODg0MC0yMDI2LTExLTE2LWVu\/tiny\/Corbus-Pharmaceuticals-Holding.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed Corresponding significant reductions were also seen in waist circumference and body mass index (BMI) Treatment-emergent psychiatric adverse events (AEs) were infrequent, mostly mild, and in line with published GLP-1 data No serious or severe psychiatric AEs were reported, including no cases of severe or serious suicidality or depression Vomiting, nausea, and constipation occurred at lower rates and were milder than those reported in published studies of oral GLP-1s NORWOOD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), a clinical-stage company focused on developing new therapies in oncology and obesity, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021273","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed Corresponding significant reductions were also seen in waist circumference and body mass index (BMI) Treatment-emergent psychiatric adverse events (AEs) were infrequent, mostly mild, and in line with published GLP-1 data No serious or severe psychiatric AEs were reported, including no cases of severe or serious suicidality or depression Vomiting, nausea, and constipation occurred at lower rates and were milder than those reported in published studies of oral GLP-1s NORWOOD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), a clinical-stage company focused on developing new therapies in oncology and obesity, &hellip; Continue reading &quot;Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T13:37:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026\",\"datePublished\":\"2026-11-16T13:37:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/\"},\"wordCount\":1276,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/\",\"name\":\"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==\",\"datePublished\":\"2026-11-16T13:37:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/","og_locale":"en_US","og_type":"article","og_title":"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026 - Market Newsdesk","og_description":"CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed Corresponding significant reductions were also seen in waist circumference and body mass index (BMI) Treatment-emergent psychiatric adverse events (AEs) were infrequent, mostly mild, and in line with published GLP-1 data No serious or severe psychiatric AEs were reported, including no cases of severe or serious suicidality or depression Vomiting, nausea, and constipation occurred at lower rates and were milder than those reported in published studies of oral GLP-1s NORWOOD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), a clinical-stage company focused on developing new therapies in oncology and obesity, &hellip; Continue reading \"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T13:37:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026","datePublished":"2026-11-16T13:37:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/"},"wordCount":1276,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/","name":"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==","datePublished":"2026-11-16T13:37:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODEwMyM3OTY3MTY3IzUwMDExODg0MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesityweek-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek\u00ae 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021273"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021273\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}